Canadian Ticagrelor Survey

AstraZeneca

Status: Completed

Conditions: Acute Coronary Syndrome

Study type: Observational

Funder types: Industry

Identifiers

NCT01757483

D5130L00009

Details and patient eligibility

About

This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.

Full description

Effectiveness of risk minimisation interventions for ticagrelor in Canada

Enrollment: 244 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• N/A (All prescribers will be contacted for participation)

Exclusion criteria

• Participation in a previous wave of the survey.

Trial design

244 participants in 1 patient group

Prescribers